High on-clopidogrel platelet reactivity and chronic kidney disease: a meta-analysis of literature studies

References

• Yahalom G, Schwartz R, Schwammenthal Y, et al. Chronic kidney disease and clinical outcome in patients with acute stroke. Stroke. 2009;40:1296–1303.
   PubMed Web of Science ®Google Scholar
• Mostofsky E, Wellenius GA, Noheria A, et al. Renal function predicts survival in patients with acute ischemic stroke. Cerebrovasc Dis. 2009;28:88–94.
   PubMed Web of Science ®Google Scholar
• Amarenco P, Callahan A, 3rd, Campese VM, et al. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial. Stroke. 2014;45:2974–2982.
   PubMed Web of Science ®Google Scholar
• Polzin A, Kelm M, Zeus T. Impaired clopidogrel antiplatelet effects and age: Young patients at risk. Int J Cardiol. 2015;187:216–218.
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003;107:87–92.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Pan Y, Wu Y, et al. Effect of estimated glomerular filtration rate decline on the efficacy and safety of clopidogrel with aspirin in minor stroke or transient ischemic attack: CHANCE Substudy (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events). Stroke. 2016;47:2791–2796.
   PubMed Web of Science ®Google Scholar
• Htun P, Fateh-Moghadam S, Bischofs C, et al. Low responsiveness to clopidogrel increases risk among CKD patients undergoing coronary intervention. J Am Soc Nephrol. 2011;22:627–633.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Capodanno D, et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. J Am Coll Cardiol. 2010;55:1139–1146.
   PubMed Web of Science ®Google Scholar
• Baber U, Mehran R, Kirtane AJ, et al. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents registry. Circ Cardiovasc Interv. 2015;8:e001683.
   PubMed Web of Science ®Google Scholar
• Morel O, El Ghannudi S, Jesel L, et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel. J Am Coll Cardiol. 2011;57:399–408.
   PubMed Web of Science ®Google Scholar
• Muller C, Caillard S, Jesel L, et al. Association of estimated GFR with platelet inhibition in patients treated with clopidogrel. Am J Kidney Dis. 2012;59:777–785.
   PubMed Web of Science ®Google Scholar
• Motovska Z, Odvodyova D, Fischerova M, et al. Renal function assessed using cystatin C and antiplatelet efficacy of clopidogrel assessed using the vasodilator-stimulated phosphoprotein index in patients having percutaneous coronary intervention. Am J Cardiol. 2012;109:620–623.
   PubMed Web of Science ®Google Scholar
• Viviani Anselmi C, Briguori C, Roncarati R, et al. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease. JACC Cardiovasc Interv. 2013;6:1166–1175.
   PubMed Web of Science ®Google Scholar
• Gremmel T, Muller M, Steiner S, et al. Chronic kidney disease is associated with increased platelet activation and poor response to antiplatelet therapy. Nephrol Dial Transplant. 2013;28:2116–2122.
   PubMed Web of Science ®Google Scholar
• Mangiacapra F, Cavallari I, Barbato E, et al. Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention. Am J Cardiol. 2014;113:1124–1129.
   PubMed Web of Science ®Google Scholar
• Mavrakanas TA, Alam A, Reny JL, et al. Platelet reactivity in stable cardiovascular patients with chronic kidney disease. Platelets. 2018;29:455–462.
   Google Scholar
• Maruyama H, Fukuoka T, Deguchi I, et al. Response to clopidogrel and its association with chronic kidney disease in noncardiogenic ischemic stroke patients. Intern Med. 2014;53:215–219.
   PubMed Web of Science ®Google Scholar
• Best PJ, Steinhubl SR, Berger PB, et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. Am Heart J. 2008;155:687–693.
   PubMed Web of Science ®Google Scholar
• Chen YT, Chen HT, Hsu CY, et al. Dual antiplatelet therapy and clinical outcomes after coronary drug-eluting stent implantation in patients on hemodialysis. Clin J Am Soc Nephrol. 2017;12:262–271.
   PubMed Web of Science ®Google Scholar
• Alexopoulos D, Panagiotou A, Xanthopoulou I, et al. Antiplatelet effects of prasugrel vs. double clopidogrel in patients on hemodialysis and with high on-treatment platelet reactivity. J Thromb Haemost. 2011;9:2379–2385.
   PubMed Web of Science ®Google Scholar
• Butler K, Teng R. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with severe renal impairment. J Clin Pharmacol. 2012;52:1388–1398.
   PubMed Web of Science ®Google Scholar
• Guo LZ, Kim MH, Kim TH, et al. Comparison of three tests to distinguish platelet reactivity in patients with renal impairment during dual antiplatelet therapy. Nephron. 2016;132:191–197.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007;49:1505–1516.
   PubMed Web of Science ®Google Scholar
• Michelson AD, Frelinger AL, 3rd, Furman MI. Current options in platelet function testing. Am J Cardiol. 2006;98:4N–10N.
   PubMed Web of Science ®Google Scholar
• Labarthe B, Theroux P, Angioi M, et al. Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug. J Am Coll Cardiol. 2005;46:638–645.
   PubMed Web of Science ®Google Scholar
• Redfors B, Ben-Yehuda O, Lin S-H, et al. Quantifying ischemic risk after percutaneous coronary intervention attributable to high platelet reactivity on clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents Study). Am J Cardiol. 2017;120:917–923.
   PubMed Web of Science ®Google Scholar
• Franchi F, Rollini F, Angiolillo DJ. Defining the link between chronic kidney disease, high platelet reactivity, and clinical outcomes in clopidogrel-treated patients undergoing percutaneous coronary intervention. Circ Cardiovasc Inte. 2015;8:e002760.
   PubMedGoogle Scholar
• Parodi G, Marcucci R, Valenti R, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA. 2011;306:1215–1223.
   PubMed Web of Science ®Google Scholar